Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment

Abstract

(1) Inverse psoriasis (IP), also known as intertriginous, typically affects the groin, armpits, navel, intergluteal fissure, and external genitalia. Skin lesions are erythematous plaques of inflammatory nature, smooth, well-delimited, non-scaly, and non-infiltrated. Lesions may be accompanied by itching, pain, or burning sensation. The aim of this study is both to investigate the modulation of the skin microbiota induced by IP and, on the other hand, to test the effectiveness of the new biotechnological product LimpiAL 2.5%. (2) Patients affected by IP were recruited in a private practice and treated for 4 weeks with LimpiAL 2.5% exclusively. The clinical effects on the lesion skin were evaluated, and the skin microbiotas before and after treatment were compared. (3) The clinical outcomes reveled a significant beneficial effect of the tested product. At the same time, LimpiAL increased the biological diversity of the skin microbiota and exerted a significant decrease of some Corynebacterium species, and the increase of some Staphylococcus species. (4) Together, the clinical outcomes and the microbiota analysis suggest that LimpiAL treatment improves the skin condition of affected patients, basically restoring the eubiosis conditions of the affected sites and modulating the bacterial composition of the resident microbiota.

Targeting S. aureus Extracellular Vesicles: A New Putative Strategy to Counteract Their Pathogenic Potential

“…To this end, we evaluated the efficacy of a wall fragment derived from the patented strain of C. acnes DSM28251 (provided by Aileens Pharma S.r.l., Nova Milanese, MB, Italy). This wall fragment, referred to as c40 (DEPOSIT: 9517149, Aileens Pharma S.r.l., Nova Milanese, MB, Italy), was tested both independently and in combination with a mucopolysaccharide carrier, specifically hyaluronic acid (HAc40) (DEPOSIT: WO2022243558A1, Aileens Pharma S.r.l., Nova Milanese, MB, Italy) [ 25 , 26 , 27 , 28 ], to counteract the pathogenic potential of extracellular vesicles (EVs) produced by S. aureus ATCC 14458.…”

Editorial: Special Issue, “Molecular Advances in Skin Diseases 2.0”

“…LimpiAL increased the biological diversity of the skin microbiota and decreased some Corynebacterium species, and increased some Staphylococcus species. LimpiAL might improve IP by restoring the eubiosis conditions and modulating the bacterial composition of the resident microbiota [ 5 ].…”